8/27/2019 6:13:18 AM
Mesoblast:FDA Provides Guidance On Clinical Pathway To Marketing Application For Revascor
8/12/2019 6:03:29 AM
Mesoblast Appoints Fred Grossman As Chief Medical Officer
6/24/2019 6:27:18 AM
Mesoblast: FDA Grants Rexlemestrocel-L, Orphan Drug Designation For Prevention Of Post-implantation Mucosal Bleeding
6/11/2019 6:04:17 AM
Mesoblast And JCR Pharma Expand Japan License Agreement To Use Of Mesenchymal Stem Cells In Newborns
4/16/2019 6:09:06 AM
FDA Agrees To Rolling Review Of Mesoblast’s BLA For Cell Therapy In Children With SR-aGVHD
3/25/2019 6:04:56 AM
Mesoblast: Licensee Files For Marketing Approval To Treat Epidermolysis Bullosa
1/7/2019 6:05:33 AM
Mesoblast Completes Patient Recruitment In Events-driven Phase 3 Trial Of Revascor
12/19/2018 7:22:59 AM
Mesoblast Appoints Eric Strati To SVP, Commercial
11/11/2018 8:08:35 PM
MESO : Clinically Outcome In NIH Trial Of MPC-150-IM For Heart Failure LVAD Recipients Provides Pathway For Approval
10/24/2018 6:08:14 AM
Mesoblast Expands Partnership With JCR In Japan For Wound Healing In Patients With Epidermolysis Bullosa
10/9/2018 12:05:15 PM
Orchestra BioMed Adds Eric Rose, Jason Aryeh And Gary Pruden To Strategic Advisory Board
10/2/2018 6:05:25 AM
Mesoblast: Phase 2b Trial Of MPC-150-IM Selected As Late-Breaking Presentation At AHA Scientific Sessions
7/17/2018 6:33:02 AM
Mesoblast Enters Strategic Cardiovascular Alliance For China With Tasly Pharmaceutical Group